Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12613001187730
Ethics application status
Approved
Date submitted
28/10/2013
Date registered
29/10/2013
Date last updated
14/10/2015
Type of registration
Prospectively registered

Titles & IDs
Public title
Infectivity of the Plasmodium falciparum 7G8 malaria cell bank, MCB-004, in humans.
Scientific title
Characterisation of the in vivo infectivity of the Plasmodium falciparum 7G8 cell bank, MCB-004, in malaria naive adults.
Secondary ID [1] 283453 0
Nil
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Malaria 290375 0
Condition category
Condition code
Infection 290766 290766 0 0
Studies of infection and infectious agents

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Human red blood cells infectedwith Plasmodium falciparum 7G8
Dose: 1,800 viable Plasmodium falciparum infected red blood cells.
Mode of administration: Intra-venous injecton.
Duration: One dose at Day 0.
Patients will be actively monitored up to Day 28 post injection. A blood sample will be collected on Day 90 post infection for safety serum.
Intervention code [1] 288170 0
Treatment: Drugs
Comparator / control treatment
Nil
Control group
Uncontrolled

Outcomes
Primary outcome [1] 290758 0
Primary Outcome 1: In vivo infectivity of the P. falciparum 7G8 cell bank, MCB-004, in humans.
Assessed by thick blood smear and polymerase chain reaction on a daily basis from day 3 until day 17 post administration of P. falciparum infected red blood cells.
Timepoint [1] 290758 0
Day 3-Day 17 post administration of P. falciparum infected red blood cells.
Primary outcome [2] 290759 0
Primary Outcome 2: Safety of the P. falciparum 7G8 cell bank, MCB-004, in humans.
Assessed by frequency and type of clinical adverse events, hematology, blood chemistry, serology, physical examination including vital signs and electrocardiograms.

No adverse events attributable to this investigational product have been documented in previous studies when using this study design.
Timepoint [2] 290759 0
Active monitoring daily at enrollment and from D3-D17, D28 and D90 post administration of P. falciparum infected red blood cells. Passive monitoring (ie patients contacting and reporting any potential adverse events to study staff outside of scheduled visits) from D0-D90.
Secondary outcome [1] 305201 0
Secondary Outcome 1: Immunogenicity of the P. falciparum 7G8 cell bank, MCB-004, in humans.
Assessed by measuring malaria-specific antibody responses and T cell responses.
Timepoint [1] 305201 0
D0, Day of Drug treatment, D28, D90.

Eligibility
Key inclusion criteria
1)Volunteers will be males, aged between 18 and 45 years who do not live alone (from Day 1 until at least the end of the anti-malarial drug treatment).
2)Volunteers must have a BMI within the range 18–30.
3)Volunteers must understand the procedures involved and agree to participate in the study by giving fully informed, written consent.
4)Be contactable and available for the duration of the trial (maximum of 90 days)
5)Volunteers must be non-smokers and in good health, as assessed during pre-study medical examination and by review of screening results.
6)Good peripheral venous access.
Minimum age
18 Years
Maximum age
45 Years
Sex
Males
Can healthy volunteers participate?
Yes
Key exclusion criteria
1)History of malaria.
2)Travelled to or lived (>2 weeks) in a malaria-endemic country during the past 12 months or planned travel to a malaria-endemic country during the course of the study.
3)Has evidence of increased cardiovascular disease risk (defined as >10%, 5 year risk) as determined by the method of Gaziano et al. Risk factors include sex, age, systolic blood pressure (mm Hg), smoking status, body mass index (BMI, kg/mm2), reported diabetes status and blood pressure.
4)History of splenectomy.
5)History of a severe allergic reaction, anaphylaxis or convulsions following any vaccination, infusion or treatment with the anti-malarial drugs artemether and/or lumefantrine.
6)Presence of current or suspected serious chronic diseases such as cardiac or autoimmune disease (HIV or other immunodeficiencies), insulin dependent diabetes, progressive neurological disease, severe malnutrition, acute or progressive hepatic disease, acute or progressive renal disease, psoriasis, rheumatoid arthritis, asthma, epilepsy or obsessive compulsive disorder, skin carcinoma excluding non-spreadable skin cancers such as basal cell and squamous cell carcinoma.
7)Known inherited genetic anomaly (known as cytogenetic disorders)e.g., Down’s syndrome.
8)Individuals wishing to donate blood to the Australian Red Cross Blood Service during the study or within 6 months of administration of the malaria inoculum.
9)The volunteer has a diagnosis of schizophrenia, severe depression, bi-polar disease, or other severe (disabling) chronic psychiatric diagnosis. Participants who are receiving a single antidepressant drug and are stable for at least 3 months prior to enrollment without decompensating may be allowed to enroll in the study at the investigator’s discretion.
10)Known pre-existing prolongation of the QTc interval. Family history of congenital prolongation of the QTc interval on electrocardiograms or of sudden death or any other clinical condition known to prolong the QTc interval, e.g. volunteers with a history of symptomatic cardiac arrhythmias, with clinically relevant bradycardia or with severe cardiac disease.
11)Recent or current therapy with an antibiotic or drug with potential anti-malarial activity (tetracycline, azithromycin, clindamycin, hydroxychloroquine etc).
12)Concomitant use of any drug which is metabolised by the cytochrome enzyme CYP2D6 (e.g. flecainide, metoprolol, imipramine, amitriptyline, clomipramine) OR drugs that are known to prolong the QTc interval, e.g. antiarrhythmics of classes IA and III, neuroleptics, antidepressant agents, certain antibiotics (including some agents of the following classes: macrolides, fluoroquinolones, imidazole and triazole antifungal agents), certain nonsedating antihistamines (terfenadine, astemizole), cisapride.
13)Use of corticosteroids, anti-inflammatory drugs, any immunomodulators or anticoagulants. Currently receiving or have previously received immunosuppressive therapy, including systemic steroids including ACTH or inhaled steroids in dosages which are associated with hypothalamic-pituitary-adrenal axis suppression such as 1mg/kg/day of prednisone or its equivalent or chronic use of inhaled high potency corticosteroids (budesonide 800 microgram per day or fluticasone 750 microgram).
14)Presence of acute infectious disease or fever (e.g., sub-lingual temperature greater than or equal to 38.5°C) within the five days prior to study product administration).
15)Evidence of acute illness within the four weeks before trial prior to screening.
16)Significant intercurrent disease of any type, in particular liver, renal, cardiac, pulmonary, neurologic, rheumatologic, or autoimmune disease by history, physical examination, and/or laboratory studies including urinalysis.
17)Alcohol consumption greater than community norms (i.e. more than 21 standard drinks per week for males).
18)A history of drug habituation, or any prior intravenous usage of an illicit substance.
19)Medical requirement for intravenous immunoglobulin or blood transfusions.
20)Participation in any investigational product study within the 8 weeks preceding the study.
21)Participation in any research study involving significant blood sampling, or blood donation to Red Cross (or other) blood bank during the 8 weeks preceding the reference drug dose in the study.
22)Have ever received a blood transfusion.
23)Positive test for HIV, Hepatitis B, hepatitis C, Human T-cell Lymphotropic Virus I & II (HTLVI & HTLVII), TB or syphilis.
24)Any clinically significant biochemical or haematologic abnormality (Hb must be greater than or equal to 13.5g/dL).
25)Ingestion of any poppy seeds within the 48 hours prior to the screening blood test
(volunteers will be advised by phone not to consume any poppy seeds in this time period).
26)Detection of any of the following drugs ( Amphetamines, Methamphetamines, Barbiturates, Benzodiazepines, Cocaine, Methadone, Opiates, Phencyclidine, Tetrahydrocannabinols, Tricyclic antidepressants) in the urine drug screen unless there is an explanation acceptable to the medical investigator (e.g. the subject has stated in advance that they consumed a prescription or OTC product which contained the detected drug) and/or the subject has a negative urine drug screen on retest by the pathology laboratory.
27)Evidence of any condition that, in the opinion of the clinical investigator, might interfere with the evaluation of the study objectives or pose excessive risks to participants.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Not applicable
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Not applicable
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 0
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
2/12/2013
Actual
13/01/2014
Date of last participant enrolment
Anticipated
Actual
3/02/2014
Date of last data collection
Anticipated
Actual
Sample size
Target
2
Accrual to date
Final
2
Recruitment in Australia
Recruitment state(s)
QLD

Funding & Sponsors
Funding source category [1] 288174 0
Charities/Societies/Foundations
Name [1] 288174 0
The Atlantic Philanthropies
Country [1] 288174 0
Australia
Primary sponsor type
University
Name
Griffith University
Address
c/- Chris Davis
Griffith University, Gold Coast Campus
Institute for Glycomics, Building G26
Parklands Drive
Southport 4222
QLD
Country
Australia
Secondary sponsor category [1] 286896 0
None
Name [1] 286896 0
Not applicable
Address [1] 286896 0
Not applicable
Country [1] 286896 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 290087 0
Griffith University Human Research Ethics Committee
Ethics committee address [1] 290087 0
Griffith University,Gold Coast Campus,
Rm 3.60, Sciece, Engineering and Architecture (G39)
Parklands, 4222 QLD.
Ethics committee country [1] 290087 0
Australia
Date submitted for ethics approval [1] 290087 0
22/10/2013
Approval date [1] 290087 0
12/11/2013
Ethics approval number [1] 290087 0
GLY/08/13/HREC

Summary
Brief summary
This study is examining the infectivity of a Plasmodium falciparum 7G8 malaria cell bank in humans. Participants will receive a single inoculum of the malaria cell bank, which consists of human red blood cells containing P. falciparum 7G8 malaria parasites. Followng administration of the inoculum, we will measure the growth of the malaria parasites in the blood-stream and then administer anti-malarial treatment (Riamet) according to specific criteria (based on the number of parasites in the blood as well as clinical signs/symptoms of malaria). We will also be assessing the safety of the inoculum and also the way the immune system responds to it. Determining the infectivity and safety of the malaria cell bank is important as it will form a critical part of future clinical trials investigating the effectiveness of a new malaria vaccine that is currently being developed.
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 43858 0
Prof Michael Good
Address 43858 0
c/- Griffith University, Gold Coast Campus, Institute for Glycomics, Building G26, Paklands Drive, Southport, 4222. QLD.
Country 43858 0
Australia
Phone 43858 0
61 7 555 28051
Fax 43858 0
61 7 555 28098
Email 43858 0
[email protected]
Contact person for public queries
Name 43859 0
Danielle Stanisic
Address 43859 0
c/- Griffith University, Gold Coast Campus, Institute for Glycomics, Building G26, Paklands Drive, Southport, 4222. QLD.
Country 43859 0
Australia
Phone 43859 0
61 7 555 28051
Fax 43859 0
61 7 555 28098
Email 43859 0
[email protected]
Contact person for scientific queries
Name 43860 0
Michael Good
Address 43860 0
c/- Griffith University, Gold Coast Campus, Institute for Glycomics, Building G26, Paklands Drive, Southport, 4222. QLD.
Country 43860 0
Australia
Phone 43860 0
61 7 555 28051
Fax 43860 0
61 7 555 28098
Email 43860 0
[email protected]

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
SourceTitleYear of PublicationDOI
Dimensions AIInfectivity of Plasmodium falciparum in Malaria-Naive Individuals Is Related to Knob Expression and Cytoadherence of the Parasite2016https://doi.org/10.1128/iai.00414-16
N.B. These documents automatically identified may not have been verified by the study sponsor.